Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SAVA
stocks logo

SAVA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
0.000
-100%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Cassava Sciences, Inc. (SAVA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 53.70%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+53.70%
In Past 3 Month
Wall Street analysts forecast SAVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SAVA is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast SAVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SAVA is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.320
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 3.320
sliders
Low
8.00
Averages
8.00
High
8.00
HC Wainwright & Co.
Vernon Bernardino
Hold
Reiterates
$2
2025-03-25
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$2
2025-03-25
Reiterates
Hold
Reason
HC Wainwright & Co.
Vernon Bernardino
Hold
Reiterates
n/a
2025-03-04
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
n/a
2025-03-04
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cassava Sciences Inc (SAVA.O) is 0.00, compared to its 5-year average forward P/E of -5.38. For a more detailed relative valuation and DCF analysis to assess Cassava Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.38
Current PE
0.00
Overvalued PE
39.79
Undervalued PE
-50.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
24.00
Undervalued EV/EBITDA
-28.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
18.44
Current PS
0.00
Overvalued PS
60.27
Undervalued PS
-23.40
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 3083.17% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SAVA News & Events

Events Timeline

(ET)
2025-11-12
08:09:08
Cassava Sciences announces Q3 earnings per share of 22 cents, compared to a loss of 58 cents in the previous year.
select
2025-10-22 (ET)
2025-10-22
08:10:58
Cassava Sciences Names Dawn Bir to Board of Directors
select
2025-08-14 (ET)
2025-08-14
07:36:08
Cassava Sciences reports Q2 EPS (92c) vs 13c last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03SeekingAlpha
PinnedCassava Sciences Faces FDA Demand for Additional Data on Simufilam Study

  • FDA Request for Information: Cassava Sciences has received a request from the FDA for additional information regarding its investigational new drug application for simufilam, which is intended for treating tuberous sclerosis complex-related epilepsy.

  • Impact on Clinical Study Timeline: The FDA's request may delay the start of the proposed clinical study, although Cassava still aims to begin its proof-of-concept trial in the first half of 2026.

  • Market Reaction: Following the news, SAVA shares initially fell by 13% in premarket trading but later recovered to show a 1% increase.

  • Company Developments: Cassava Sciences has been active in the market, including insider stock purchases and filing a $200 million mixed securities shelf.

[object Object]
Preview
5.0
11-25SeekingAlpha
Cassava Sciences Shares Surge 10% Post-Market Following CEO Stock Purchase

  • Stock Price Surge: Cassava Sciences experienced a 10% increase in after-market trading following an SEC filing revealing CEO Richard Barry's significant stock purchase.

  • CEO's Share Acquisition: Barry acquired 150,000 shares at an average price of $4.76, totaling approximately $414,000, bringing his total ownership to over 938,000 shares.

  • Company Developments: The news comes alongside Cassava Sciences' filing for a $200 million mixed securities shelf, indicating potential future fundraising efforts.

  • Market Analysis: Seeking Alpha has provided a Quant Rating on Cassava Sciences, reflecting ongoing interest and analysis of the company's financial health and market position.

[object Object]
Preview
5.0
11-21SeekingAlpha
Cassava Sciences Soars After CEO Purchases Shares

  • Insider Stock Purchase: Cassava Sciences' CEO Richard Barry purchased approximately 73.4K shares at $2.75 each, totaling nearly $201.8K, increasing his ownership to over 788K shares.

  • Company Performance: The company's stock rose about 5% in premarket trading, despite a nearly 90% decline in value over the past year due to setbacks in its Alzheimer's drug research program.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cassava Sciences Inc (SAVA) stock price today?

The current price of SAVA is 3.32 USD — it has increased 7.1 % in the last trading day.

arrow icon

What is Cassava Sciences Inc (SAVA)'s business?

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

arrow icon

What is the price predicton of SAVA Stock?

Wall Street analysts forecast SAVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SAVA is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cassava Sciences Inc (SAVA)'s revenue for the last quarter?

Cassava Sciences Inc revenue for the last quarter amounts to -11.86M USD, decreased -61.27 % YoY.

arrow icon

What is Cassava Sciences Inc (SAVA)'s earnings per share (EPS) for the last quarter?

Cassava Sciences Inc. EPS for the last quarter amounts to -6301000.00 USD, decreased -65.59 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cassava Sciences Inc (SAVA)'s fundamentals?

The market is revising No Change the revenue expectations for Cassava Sciences, Inc. (SAVA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 53.70%.
arrow icon

How many employees does Cassava Sciences Inc (SAVA). have?

Cassava Sciences Inc (SAVA) has 30 emplpoyees as of December 05 2025.

arrow icon

What is Cassava Sciences Inc (SAVA) market cap?

Today SAVA has the market capitalization of 160.38M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free